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Summary Monoclonal antibodies were raised against human placental soluble E-cadherins and used in an
immunoenzymometric assay to detect soluble E-cadherins in biological fluids. The E-cadherin assay was
accurate enough to quantitate the concentration of soluble E-cadherin in the cell culture supernatants.
Immunoreactive E-cadherins, identified as existing in the soluble form in normal serum, were shown to have
apparent lower molecular mass (approximately 80 kDa) than intact molecules of E-cadherin. We found that
the immunoreactive E-cadherin levels in the serum of the studied cancer patients were significantly elevated
(mean ± s.d. 3.80 ± 2.36 tig ml', P<0.0001) when compared with the normal levels (1.99 ± 0.50 1tgml-'). We
also found that serum E-cadherin levels in the 22 patients with gastric cancer (3.51 ± 1.78tLgml-, P<0.02)
or the 11 patients with hepatocellular cancer (5.55 ± 3.11 Lg ml-', P<0.001) were significantly higher than
those in the 26 diabetic patients (2.33 ± 1.58 iLg ml-'). Of the 54 cancer patients, 53.7% exhibited an elevated
amount of soluble E-cadherin in serum. Thus, it is evident that soluble E-cadherin in circulation can be used
as a prospective tumour marker that accurately reflects the progressive regeneration of E-cadherin at tumour
sites, potentially induced by tumour-associated proteolytic degradation.
Cadherins are Ca2"-dependent cell adhesion molecules which
play an essential role in normal growth and development via
mediation of homotypic, homophilic cell-cell association
(Takeichi, 1988). A variety of subclasses of cadherins have
already been identified (Suzuki et al., 1991). Three of them,
namely E-, N- and P-cadherin, share a common primary
structure and mediate cell-cell adhesion in a homophilic and
subclass-specific manner (Takeichi, 1991). E-cadherin, also
termed uvomorulin or Cell-CAM120/80, is a cell-adhesive
molecule found in epithelial cells in a variety of embryonic
and adult tissues (Damsky et al., 1983; Ogou et al., 1983;
Vestweber & Kemler, 1984). Several recent studies suggested
that loss of E-cadherin may be associated with tumour pro-
gression in epidermal carcinogenesis as well (Navarro et al.,
1991), and E-cadherin acts particularly as a suppressor of
invasive ability (Behrens et al., 1989; Chen & Obrink, 1991;
Frixen et al., 1991; Mareel et al., 1991; Vleminckx et al.,
1991) or metastatic phenotype (Hashimoto et al., 1989;
Schipper et al., 1991). In adult organisms, each cadherin
displays a characteristic tissue distribution pattern, although
expression is not tissue specific (Takeichi, 1991). Many
immunohistochemical studies searching for tissue distribution
of cadherins have demonstrated that unstable or reduced
expression of E-cadherin seems to be a common event in
cancer progression, e.g. in lung carcinoma (Shimoyama et al.,
1989), gastric tumours (Shimoyama & Hirohashi, 1991a),
hepatocellular carcinoma (Shimoyama & Hirohashi, 1991b),
breast carcinoma (Rasbridge et al., 1993) and prostatic
tumours (Bussemakers et al., 1992; Umbas et al., 1992).
Soluble forms of E-cadherin were firstly investigated as
80-84 kDa peptides released from MCF-7 human carcinoma
cells into the serum-free culture medium or artificially
generated by trypsinising cells in the presence of calcium
(Damsky et al., 1983). They retain the functional activities
themselves to disrupt cell-cell contact in cultured epithelial
cells, and antibodies raised against them also induce disrup-
tion of mutual adhesion of the target cells (Wheelock et al.,
1987). Therefore, the 80 kDa peptide is probably a degrada-
tion product of the 120 kDa form of intact E-cadherin
generated by a Ca2+ ion-dependent proteolytic action
(Wheelock et al., 1987; Takeichi, 1988). These curious soluble
fragments are presumed to be a good indicator to monitor
the regeneration of E-cadherin in vivo, but none has been
identified as present in the soluble form in biological fluids of
animal bodies to date. Here, we show that the immunoen-
zymometric assay for measuring the fluid-phase E-cadherin
was constructed using monoclonal antibodies, in order to
gain insight into the nature of the mechanisms regarding
remodelling or loss of E-cadherin during carcinogenesis.
Immunoreactive E-cadherin in a soluble form was found to
be apparently circulating in biological fluids of healthy per-
sons, and it consisted of molecules smaller than those of
intact transmembrane-type protein. Serum levels of soluble
E-cadherin are significantly elevated in patients with malig-
nancy, indicating that these soluble cell adhesion molecules
may be of diagnostic importance for monitoring the
epithelial tumour progression.
Materials and methods
Immunogen
Human soluble E-cadherin was purified from the supernatant
of fresh placenta extract, which was prepared by
homogenisation in 0.02 mol 1-' Tris-HCI buffer (pH 7.4)
containing 0.15 mol l- sodium chloride and 0.01 mol 1' cal-
cium chloride (TBS) at 4'C. HECD-1 murine monoclonal
antibodies (MAbs) were purchased from Takara Shuzo
(Kyoto, Japan), and 10 mg of immunoglobulin G (IgG) was
coupled to a cyanogen bromide (CNBr)-activated Sepharose
4B column (Pharmacia LKB Biotechnology, Uppsala,
Sweden). Water-insoluble residual materials were removed
after centrifugation at 10,000g for 30min, and the extracts
were then applied onto the immobilised HECD-1 on the
column, followed by 4-fold dilution with TBS containing
0.1% sodium azide. After washing the column with excess
TBS, the materials bound on the column were eluted by TBS
containing 8 mol I` urea and further dialysed against TBS at
4°C for 36 h. Finally, we obtained the soluble human E-
cadherin by immunopurifying it again using immobilised
HECD-1 according to the above procedure, and it was
separated and stored at -80'C until being used as
immunogen or standard for the immunoenzymometric assays
(IEMAs).
Monoclonal antibodies
Nine hybridomas secreting different MAbs were prepared by
fusion of mouse myeloma cells P3-X63-Ag8-Ul with spleen
cells from Balb/c mice immunised with purified soluble E-
cadherin according to the standard hybridoma technology
(Harlow & Lane, 1988). MAbs were initially screened by
enzyme-linked immunosorbent assay (ELISA) for their
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ability to react with antigen immobilised on the microtitre
plates, or to preferentially bind with the fixed human vulvar
epidermoid carcinoma cell line A431 (Giard et al., 1973) on
the culture dish, which was prepared by fixing cultured cells
spreading on the plates directly with the solution of 99%
ethanol and 1% acetic acid at 4°C for 3 min.
Immunoblotting
The immunoreactivities of the established MAbs to E-
cadherin expressed on A431 cells were analysed by immuno-
blotting as described previously (Yoshida-Noro et al., 1984)
with slight modification. In brief, monolayers of A431 cells
(1 x 106cells) were incubated with 5 ml of solution of
physiological saline containing 1 mmol 1- EDTA and 0.01%
trypsin, 0.01% trypsin plus 5 mmol 1' calcium chloride or
only 5 mmol 1i calcium chloride at 37°C for 20 min. Treated
cells were isolated by gentle pipetting or by using cell
scrapers (Becton Dickinson, Lincoln Park, NJ, USA), cent-
rifuged at 800g for Omin, and the supernatant was
separated from the insoluble cellular materials. The cells and
supernatants were then extracted with 4% sodium dodecyl
sulphate (SDS) electrophoresis sample solution
(0.1 mol 1-' Tris-HCI, 5% P-mercaptoethanol, 20% glycerol,
0.005% bromophenol blue, pH 7.6) at a volume ratio of 1:1,
subjected to 5-20% SDS-polyacrylamide gel electrophoresis
(PAGE), and transferred onto the polyvinylidine difluoride
(PVDF) membrane (Millipore, Bedford, MA, USA). The
membranes were blocked by TBS containing 0.1% skimmed
milk and incubated in the hybridoma culture supernatants
for 4 h at room temperature. Immunoreactive proteins on the
membranes were visualised by peroxidase-labelled anti-mouse
IgG (Amersham International, Amersham, UK) and 4-
chloro-l-naphthol substrate (Nacalai Tesque, Kyoto, Japan).
A 100pl aliquot of serum from the clinical subjects was
incubated with 30jg of SHE13-6 MAb immobilised on
CNBr-activated Sepharose 4B gel for 0.5 h at 4°C, and
washed twice with TBS containing 0.1% sodium azide. These
gels were directly mixed with the above sample solution,
boiled at 100°C for 2 min, and their resulting supernatants
separated by centrifugation at 4°C were subjected to the
immunoblotting analysis exactly according to the above pro-
cedures.
IEMA procedure
Among the obtained MAbs directed to soluble E-cadherin
isolated from human placenta, SHE13-6 was found to show
the highest reactivity with soluble E-cadherin. The IEMA
using MAbs was performed as previously described
(Katayama et al., 1992) with slight modifications. SHE13-6
and HECD-1 MAbs were isolated by ammonium precipita-
tion from mouse ascites, and further purified by Mono-Q
ion-exchange chromatography in the fast protein liquid
chromatography system (Pharmacia LKB). Purified soluble
E-cadherin was used as the IEMA standard. Purified SHE13-
6 was conjugated with horseradish peroxidase (Boehringer
Mannheim, Germany) using the periodate method as des-
cribed previously (Harlow & Lane, 1988). First, the wells of
the microtitre plates (Nunc, Roskilde, Denmark) were coated
with 200 il each of purified HECD-1 antibodies at an IgG
concentration of 10 sgmI-' at 4°C for 24h, and were then
blocked with bovine serum albumin (BSA) (Sigma) at room
temperature for 2 h. Human serum samples were diluted 40
times with TBS containing 1% BSA before assay. To each
well, 100 l of standard soluble E-cadherin (0, 50, 100, 200,
400, 800ngml-') or a clinical sample was added. After the
plates were incubated for 1 h, the wells were washed twice
with TBS. Then, 1001tl of a solution of peroxidase-labelled
SHE13-6 MAbs was added to the wells. The plate was
incubated for 1 h at room temperature and washed twice
with TBS. Then, 5.5 mmol 1' o-phenylenediamine dihy-
drochloride (Sigma) solution containing 0.01% hydrogen
peroxide was added to the wells as the substrate and the
mixture was left for 15 min in the dark at room temperature,
after which the enzyme reaction was terminated by the addi-
tion of 100i1 of 0.5 M sulphuric acid. The absorbance at
492 nm was measured using a Titertek Multiscan (Flow
Laboratories, McLean, VA, USA).
Subjects
We studied serum samples collected from a total of 140
individuals, including 56 healthy subjects, 26 patients with
diabetes mellitus, four patients with acute hepatitis and 54
cancer patients. There were 21 male, 29 female and six
volunteers whose genders are not specified among these heal-
thy subjects, whose serum samples were generously provided
by M. Handa (Blood Center, Keio University Hospital,
Tokyo, Japan). The primary tumour site of the cancer
patients in this study was either the stomach (n = 22), the
liver (n = 11), the pancreas (n = 1), the colon, the rectum
(n = 4) or the ovary (n = 1). Patients with leiomyosarcoma
(n = 4) and patients with leukaemia, including five patients
with myelogenous leukaemia, three with monocytic
leukaemia and three with lymphatic leukaemia (n = 11), were
also included among the cancerous subjects. Serum samples
of the 54 cancer patients, the 26 non-malignant patients with
diabetes mellitus, and the four non-malignant patients with
acute hepatitis were received from Takeda Hospital (Kyoto,
Japan). All of the 54 cancer patients with pathologically and
histologically proven cancer, but with no previous treatment
by chemotherapy and radiotherapy, were included in this
study. All the specimens of the 54 cancer patients were
collected before surgery. All of the 26 diabetic patients were
assessed as having apparent diabetes mellitus only on the
basis of abnormal levels of venous blood glucose or plasma
fructosamine, and we could not obtain any other clinical
details of individuals, such as ponderal index, duration of
diabetes, drug treatment, presence of renal impairment or
vascular disease. The patients with acute hepatitis were diag-
nosed in view of their elevated serum levels for aspartate and
alanine transaminases. The two-tailed Student's t-test was
used to compare data between different groups. The data are
presented as means ± s.d. Differences of P<0.05 were con-
sidered to be statistically significant.
Cell culture
The A431 cell line was obtained from the American Type
Culture Collection (Rockville, MD, USA), and cultured in
RPMI-1640 medium (Nissui Pharmaceuticals, Tokyo, Japan)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS). After the cultured supernatants were aspirated com-
pletely, semiconfluent monolayers of A431 (1 x 106 cells per
culture dish) were cultured for 12 h with 2 ml medium of 4%
FBS-supplemented RPMI-1640 containing EDTA at the final
concentrations of 0.0625, 0.125, 0.25, 0.5, 1 or 2mmol -'.
The soluble E-cadherin concentration of each culture super-
natant was measured by the above IEMA method.
Results
Characterization ofMAbs
HECD-1 (Shimoyama et al., 1989) and SHE13-6 MAbs were
determined to be IgGI subclasses essentially according to the
ELISA method as described previously (Harlow & Lane,
1988). One characteristic feature of the cadherin family pro-
tein is a sensitivity to degradation by trypsin, which can be
blocked by adding Ca2A to the reaction mixture (Yoshida-
Noro et al., 1984). HECD-1 was shown to react with SDS
lysates of A431 cells and those pretreated with trypsin plus
Ca2", and not to bind to A431 lysates prepared in the
absence of Ca2" (Figure 1), demonstrating that HECD-1
MAb was specific for human E-cadherin. In another Western
blotting analysis, we also found that SHE13-6 could recog-
nise soluble 80kDa fragments of E-cadherin isolated from
human placenta as well as HECD-1.582 M. KATAYAMA et al.
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Figure 1 Immunoblotting analysis for E-cadherin isolated from
human placenta or cultured cells. Insoluble materials (lanes
A-C) and supernatants (lane D) of A431 cells, trypsinised in
physiological saline containing I mmol 1' EDTA (lane A), tryp-
sinised in 5 mmol I -I calcium chloride (lanes B and D) and
extracted in saline containing 5 mmol l' calcium chloride (lane
C) were used as samples for 10% SDS-PAGE. Immunopurified
placental E-catherin (lane E) was separated on the same gels,
transferred onto the membrane and visualised by the immunob-
lotting procedure as described in Materials and methods.
IEMAfor E-cadherin
Soluble E-cadherin isolated from human placenta was
purified into a homogeneous molecule which migrated as an
80 kDa peptide on SDS-PAGE gel, and was highly reactive
to both HECD-1 and SHE13-6 MAbs in the ELISA. There-
fore, we fixed this material for use as an assay standard for
quantitation of antigen levels in several biological fluids.
Soluble E-cadherin antigens in serum samples from 56 heal-
thy individuals were actually detected by the sandwich IEMA
using immobilised HECD-1 and enzyme-labelled SHE13-6
(mean ± s.d. 1.99 ± 0.50 tg ml-'). The precision of this
IEMA was tested by assaying serum samples obtained from
four healthy donors 20 times (intra-assay) and in ten con-
secutive assays (interassay), and their coefficient of variation
values were all under 10%. The dilution curves for the five
serum samples appeared to be linear, suggesting that the
same immunoreactive substances were accurately measured in
the different dilution series (Figure 2). We found that the
most moderate measurement for soluble E-cadherin in ser-um
was performed by 40-fold dilution of all the samples from 56
healthy individuals. In the 50 healthy individuals entered in
this study, serum E-cadherin levels in 15 subjects with ages
ranging from 21 to 30 years (1.85 ± 0.55 Lgml-') were not
significantly lower than those in eight with ages ranging from
31 to 40 (2.14 0.51), those in eight with ages ranging from
41 to 50 (2.04 0.32), those in ten with ages ranging from 51
to 60 (2.23 ± 0.63), those in three with ages ranging from 61
to 70 (2.11 ± 0.24), those in three with ages ranging from 71
to 80 (2.09 ± 0.13) or those in three with ages over 81
(2.15 ± 0.20). We also found that mean level for serum E-
cadherin in 21 healthy men was not significantly higher
(1.98 ± 0.61) than that in 21 healthy women (1.97 ± 0.46).
Serum levels for E-cadherin in the healthy subjects, the non-
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Figure 2 Dilution curves of five serum samples from a healthy
subject (0) and patients with gastric tumour (0), hepatocellular
tumour (A), colon tumour (A) and leiomyosarcoma (A).
malignant patients with diabetes mellitus or acute hepatitis
and the patients with tumours are shown in Figure 3. As
compared with the normal levels obtained above,
significantly elevated levels of soluble E-cadherins in serum
were observed in the 54 cancer patients (3.80 ± 2.36,
P<0.0001), but were not in the 26 patients with diabetes
mellitus (2.33 ± 1.58). The serum E-cadherin levels in 22
patients with gastric cancers (3.51 ± 1.79 jigml1',
P<0.0001), those in 11 patients with hepatocellular car-
cinomas (5.55 ± 3.11, P<0.0001) and those in ten patients
with other cancers (3.93 ± 2.75, P<0.0001) were found to be
significantly elevated compared with those in 56 healthy sub-
jects. The levels in 11 patients with leukaemia (2.52 ± 1.00,
P<0.01) were found to be elevated significantly compared
with those in 56 healthy subjects, but their values were not
significantly higher than those in 26 diabetic patients (Figure
3). In contrast to leukaemic patients, 22 patients with gastric
tumour, 11 patients with hepatocellular tumour and ten
patients with the other tumours obviously had higher levels
of circulating E-cadherin than the diabetic patients (P<0.02,
P<0.001 and P<0.05 respectively). The levels in four
patients with leiomyosarcoma included in the group of the
other cancers were found to be slightly elevated
(3.28 ± 0.72ggml1l, P<0.05) than the normal levels but not
significantly higher than those in the diabetic patients.
Another patient group with non-malignant hepatitis
exhibited normal serum E-cadherin levels
(2.34 ± 0.52 ygml-'), which were almost identical to the
levels observed in the diabetic patients.
Immunoblot analysisfor serum E-cadherin
In immunoblot analysis after 5-20% SDS-PAGE, we
initially separated the immunoisolated proteins, reactive with
immobilised SHE13-6, from serum samples of three healthy
volunteers and six cancer patients who were randomlySOLUBLE E-CADHERIN CIRCULATING IN CANCER PATIENTS
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Figure 4 Immunoblotting analysis for serum E-cadherin. Lane
A, A431 cell lysate; lanes B-G, antigen isolated from sera of six
cancer patients; lanes H-J, antigen isolated from sera of three
healthy subjects. Each lane (B-J) indicates the immunoreactive
antigen from different individuals. Serum E-cadherin was
immunoisolated using immobilised SHEl3-6 MAb and separated
on 5-20% SDS-PAGE. Molecules immunoreactive with peroxi-
dase-labelled HECD-l were visualised by the colour intensity of
substrates according to the standard Western blotting tech-
nique.
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Figure 3 Levels of soluble E-cadherin in sera of 56 healthy
subjects, 26 diabetes patients, four hepatitis patients and 54
cancer patients. Serum E-cadherin levels were determined by
IEMA. The mean level in each group is indicated by a horizontal
bar. NS, not significant.
selected from the subjects used in this study. About
75-80 kDa E-cadherin molecules present in serum were
detected by peroxidase-labelled HECD-l MAbs and sub-
strates (Figure 4). The molecular weights of soluble
E-cadherins of several serum samples, from either healthy
subjects or cancer patients, were almost all identical (Figure
4, lanes B-J). HECD-1 MAb could also bind to E-cadherins
at the approximate molecular weight of 10 kDa in the
whole-cell lysate of A431, which consisted of intact mem-
brane-associated molecules (Figure 4, lane A).
Soluble E-cadherin releasedfrom cultured cells
Physiological concentrations ofCa2" and Mg2" both approx-
imate to 0.4 mmol l'. The release of soluble E-cadherins
increased with the elevation of EDTA concentrations, rang-
ing from 0.0625 to 0.5 mmol I`, in the culture medium.
Immunoreactive soluble E-cadherins completely disappeared
in the culture fluids at EDTA concentrations of 1 mmol 1-'
or higher, because at these concentrations EDTA was recog-
nised to chelate all of the divalent cations in the culture
medium, and E-cadherin on the cell surface was greatly
degraded into undetectable smaller fragments (Yoshida &
Takeichi, 1982).
Discussion
E-cadherin was supposed to exist in serum in the monomeric
soluble form, because the same concentrations were
recovered accurately along the linear dilution curves on the
IEMA quantitation (Figure 2). IEMA was applicable
basically to the measurement of soluble E-cadherin in cit-
rated plasma, but serum was better for routine use in the
cadherin assay, as dissolved Ca2" was not removed
artificially by chelation. In the experiments using cultured
human cells, we found that a significant amount of soluble
E-cadherin was released from the monolayers of living A431
cells by the chelating action of EDTA below physiological
concentrations of divalent cations; furthermore, released
soluble E-cadherin would fail to react with MAbs under the
further enhancement of chelation (Figure 5). We identified
from this study, as well as from results obtained previously
(Yoshida & Takeichi, 1982), that coexistent Ca2+ is necessary
to stabilise the structure of soluble E-cadherin immunoreac-
tive with those MAbs.
Several reports have stated that metastatic tumour cells
might be less homotypically adhesive than their non-meta-
static counterparts, especially in immunological analysis for
the homotypic cell-cell adhesion molecules, but their con-
clusions appear to be conflicting (Lotan & Raz, 1983; Hixson
et al., 1985; Reeves, 1992). In contrast to the other cell-cell
adhesive receptors, dysfunction in the regulation of cadherin
expression might very well be involved in cancer development
and progression (Takeichi, 1991; Umbas et al., 1992). Fur-
thermore, E-cadherin is well known to be an invasive sup-
pressor in tumour progressions, because expression levels for
E-cadherins were reduced in almost all the malignant
tumours and not correlated with their metastatic abilities
(Behrens et al., 1989; Hashimoto et al., 1989). Additionally, a
recent report suggested the possibility that some carcinoma
cells lose E-cadherin expression during the process of
detaching from the primary sites and infiltrating other sites
(Matsuura et al., 1992); another elucidated that some E-
cadherin functions expressed on the cancerous cell surfaces
are impaired by loss or down-regulation of cytoplasmic pro-
teins designated 'catenins' (Shimoyama et al., 1992). Here, we
understand that E-cadherin dysfunction in tumour cells was
partly mediated by the degradation of proteases secreted
from these cells, because soluble E-cadherin with a molecular
weight of about 80 kDa remarkably increased in the circula-
tion of cancer patients (Figure 4), and it can reasonably be
derived from proteolytic digests of the cell-surface E-
cadherin.
Healthy individuals appear to have continuous E-cadherin
regeneration and to process a small amount of soluble E-
cadherin into the blood flow, resulting in a serum E-cadherin
concentration of 2 #g ml-' (Figure 3). However, elevated
levels of soluble E-cadherin were detected more frequently in
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Figure 5 Release of soluble E-cadherin from cultured A431 cells
under several concentrations of EDTA. Monolayers of A431 cells
were cultured for 12 h in RPMI-1640 medium containing 4%
FBS and EDTA at several final concentrations.
malignant patients but not in the patients with diabetes
mellitus or acute hepatitis (Figure 3). Thus, we suggest that
proteolytic degradation of E-cadherins in cancers may be
associated with malignancy, invasiveness or the metastatic
ability of tumour cells at the primary sites. No significant
elevation of circulating E-cadherin levels was observed in the
studied non-epithelial malignancies, such as leukaemias or
leiomyosarcomas, compared with the levels in the benign
disease patients. This result can potentially suggest that
serum E-cadherin fragments may be a clinical marker specific
to detecting epithelial carcinomas. However, the relationship
between soluble E-cadherin levels in the circulation and the
metastatic potency of tumours needs to be evaluated in fur-
ther clinical studies, e.g. using experimental organ metastasis
in animal models.
Recent immunohistochemical findings of decreased E-
cadherin in progressive tumours suggest that some change in
the expression level of cell-surface E-cadherin apparently
occurs in malignant tissues (Shimoyama & Hirohashi, 1991b;
Rasbridge et al., 1993). This is the first investigation in which
soluble cadherin has been found to be present in human
biological fluids. In the present study, we propounded the
novel process, which is most frequent in epithelial cancers, of
shedding E-cadherin from cell surfaces and releasing its
fragments into the circulation. Recent reports have demon-
strated that soluble forms of some cell-surface receptors that
are increased in the biological fluids of cancer patients might
be processed by proteolytic cleavage and retain the functional
activities of their original cell-surface molecules (Symons et
al., 1988; Rothlein et al., 1991). In our preliminary observa-
tion, serum E-cadherin also interfered with cell-cell adhesion
in the cultured A431 cells at a final concentration of
50 tgml 1, and the disruptive effect of purified soluble E-
cadherin is reversible because the cells resumed their normal
morphology after removal of supplemented soluble E-
cadherin (M. Katayama et al., manuscript in preparation).
Therefore, soluble E-cadherin fragments released from the
cell surface constitute a mode of down-regulation of the
cell-to-cell adhesiveness mediated by E-cadherin, resulting in
decreased responsiveness to the adjacent cell-surface E-
cadherin. The biological potency of soluble E-cadherin
released from cultured cells has already been characterised in
in vitro experiments (Wheelock et al., 1987).
Some PI-integrins have been shown to function as intercel-
lular adhesion molecules in in vitro cultured keratinocytes
(Larjava et al., 1990), and therefore the function or in vivo
localisation of integrin P in tumour cells is often compared
with that of cadherins using immunological analysis (Pig-
natelli et al., 1992). Many reports have suggested, contrary to
the findings for E-cadherin, that the surface expression of
integrin PI is uniformly elevated in metastatic tumour cells
and potentially mediates the tight adhesion of these cells to
the subendothelial matrix substratum (Feldman et al., 1991;
Martin-Padura et al., 1991). It has already been reported that
soluble integrin PI is present in the human circulation and
that serum levels of soluble integrin P are unlikely to be
elevated in cancer patients (Katayama et al., 1991). We
observed non-correlation between soluble integrin PI and
soluble E-cadherin fragments in the serum of the studied
cancer patients (data not shown). On the other hand, soluble
laminin in biological fluids was demonstrated to be mostly
fragmented and sometimes used as a tumour marker (Brocks
et al., 1986; Katayama et al., 1992). Serum laminin levels
were significantly correlated with serum E-cadherin in the
cancer patients (data not shown). This fact could suggest that
degradation, release and shedding of E-cadherin on the
tumour cells were somehow related to the proteolytic action
by those cells, required for penetrating the extracellular mat-
rix containing laminin or collagen (Goldfarb & Liotta,
1986).
Recently, catenin has been recognised as a most important
regulator of cadherin function (Nagafuchi et al., 1991).
Although the cadherin-catenin association is lost in some
tumour cell lines or disturbed by oncogenic transformation
(Shimoyama et al., 1992; Hamaguchi et al., 1993), there are
no data available with regard to the prevailing mechanisms
responsible for decreased E-cadherin staining in human
tumour tissues (Shimoyama & Hirohashi, 1991b; Rasbridge
et al., 1993). One of the answers to this could be supplied by
the previous observation that a metastatic phenotype is
induced by the genetic deletion of E-cadherin as an invasion
suppressor (Chen & Obrink, 1991; Vleminckx et al., 1991). It
is possible that E-cadherin degradation and shedding from
the tumour cell surface is due to the increase in fragmented
E-cadherin in the soluble form in the circulation of cancer
patients, independent of the genetic abnormalities ofcadherin
or cadherin-associated molecules.
In conclusion, it is evident that soluble E-cadherin frag-
ment in serum, detected by the two-site IEMA investigated
by us for the first time, can be used as an innovative tumour
marker. The levels for serum E-cadherin fragments may be
used to accurately reflect the progressive regeneration of
E-cadherin around epithelial tumours, and probably to
monitor the recurrence of cancer patients after surgical
removal of primary tumours, or to evaluate the effects of
anti-cancer treatments.
We thank Dr Makoto Handa (Blood Center, Keio University Hos-
pital, Tokyo, Japan) for providing serum samples in this clinical
study.
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